Kovitz Investment Group Partners LLC Trims Position in Insulet Co. (NASDAQ:PODD)

Kovitz Investment Group Partners LLC trimmed its position in Insulet Co. (NASDAQ:PODD - Free Report) by 20.1% in the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 12,033 shares of the medical instruments supplier's stock after selling 3,029 shares during the period. Kovitz Investment Group Partners LLC's holdings in Insulet were worth $3,141,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in PODD. Integrated Wealth Concepts LLC raised its stake in shares of Insulet by 39.1% during the 4th quarter. Integrated Wealth Concepts LLC now owns 3,562 shares of the medical instruments supplier's stock worth $930,000 after purchasing an additional 1,001 shares during the period. Syon Capital LLC grew its position in shares of Insulet by 5.6% during the 4th quarter. Syon Capital LLC now owns 1,114 shares of the medical instruments supplier's stock valued at $291,000 after acquiring an additional 59 shares during the period. Coppell Advisory Solutions LLC grew its holdings in Insulet by 135.0% during the fourth quarter. Coppell Advisory Solutions LLC now owns 282 shares of the medical instruments supplier's stock valued at $74,000 after purchasing an additional 162 shares during the period. Price T Rowe Associates Inc. MD increased its position in Insulet by 0.4% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 202,728 shares of the medical instruments supplier's stock worth $52,927,000 after buying an additional 744 shares during the last quarter. Finally, Dark Forest Capital Management LP raised its stake in shares of Insulet by 86.5% in the fourth quarter. Dark Forest Capital Management LP now owns 2,784 shares of the medical instruments supplier's stock valued at $727,000 after buying an additional 1,291 shares during the period.

Insulet Price Performance

Insulet stock traded up $6.76 during mid-day trading on Friday, hitting $257.01. 838,676 shares of the company traded hands, compared to its average volume of 717,346. The stock has a fifty day moving average price of $257.51 and a 200-day moving average price of $262.48. The stock has a market cap of $18.05 billion, a price-to-earnings ratio of 44.39, a price-to-earnings-growth ratio of 3.62 and a beta of 1.30. Insulet Co. has a one year low of $160.19 and a one year high of $289.46. The company has a debt-to-equity ratio of 1.21, a quick ratio of 2.80 and a current ratio of 3.68.

Insulet (NASDAQ:PODD - Get Free Report) last released its earnings results on Thursday, February 20th. The medical instruments supplier reported $1.15 EPS for the quarter, beating analysts' consensus estimates of $1.00 by $0.15. Insulet had a return on equity of 24.46% and a net margin of 20.19%. The business had revenue of $597.50 million for the quarter, compared to analysts' expectations of $582.02 million. On average, equities analysts predict that Insulet Co. will post 3.92 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Insulet news, Director Wayne A.I. Frederick sold 1,825 shares of the company's stock in a transaction dated Tuesday, March 25th. The shares were sold at an average price of $275.00, for a total transaction of $501,875.00. Following the completion of the sale, the director now directly owns 3,231 shares in the company, valued at $888,525. This represents a 36.10 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. 0.47% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

Several brokerages recently weighed in on PODD. Royal Bank of Canada started coverage on Insulet in a report on Thursday, March 6th. They issued an "outperform" rating and a $340.00 price objective for the company. Wells Fargo & Company set a $322.00 price target on shares of Insulet in a research report on Monday, April 28th. Wolfe Research downgraded shares of Insulet from an "outperform" rating to a "peer perform" rating in a report on Tuesday. Barclays boosted their target price on shares of Insulet from $234.00 to $266.00 and gave the company an "equal weight" rating in a report on Wednesday. Finally, Citigroup increased their target price on Insulet from $310.00 to $355.00 and gave the stock a "buy" rating in a research report on Friday, February 21st. Five research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company. According to MarketBeat, Insulet has a consensus rating of "Moderate Buy" and an average price target of $293.94.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.